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Patients with previous unprovoked venous thromboembolism (VTE) and persistent 
antiphospholipid antibodies, fulfil the criteria for antiphospholipid syndrome (APS), 
and are usually offered long term treatment with vitamin K antagonists (VKA) due to 
the risk of recurrent events [1].  
However, VKAs require regular monitoring and maintaining the INR within the target 
therapeutic range can be challenging for some. Furthermore, unique to APS, VKA 
monitoring can be complicated by the variable responsiveness of reagents used in the 
INR test to lupus anticoagulants (LA), leading to instability of anticoagulation, and an 
inaccurate reflection of the true level of anticoagulation [2].  
The world-wide approval of rivaroxaban and more latterly, other novel oral 
anticoagulants (NOAs), for the secondary prevention of VTE may represent a major 
advance for the treatment of patients with APS and previous VTE.  For a NOA 
potentially would result in improved quality of life in patients with APS who 
generally require an indefinite period of anticoagulation, because unlike warfarin, 
NOAs  do not require monitoring and have no major food or alcohol interactions and 
few reported drug interactions. 
In order to assess rivaroxaban in comparison to VKAs in the secondary prevention of 
VTE in APS, the UK-based rivaroxaban in APS (RAPS trial) is currently ongoing [3]. 
RAPS is a prospective randomised trial of warfarin versus rivaroxaban in patients 
with previous VTE and APS, with or without systemic lupus erythematosus, being 
maintained at a target INR of 2.5 (i.e. range 2.0–3.0).  
In this letter, we report our preliminary experience with rivaroxaban use in patients 
with APS with previous VTE and poor anticoagulation control with VKA. They were 
started on rivaroxaban prior to the start of the RAPS study or failed to qualify for 
RAPS (e.g. less than 18 years old). Secondly, we aimed to evaluate the diagnostic 
accuracy of lupus anticoagulant testing in patients with APS while on rivaroxaban 
comparing results with their previous tests, when they were not receiving 
anticoagulation.  
Thirty-five patients, fulfilling the current APS criteria [4] attending our Thrombosis 
Centre were included (24 female, 11 male, median age 47 [range 17-75], median 
disease duration 9 [1-18] years, median age at onset of disease 33 [15-69] years. 
Twenty-four had previous deep vein thrombosis, 11 had both deep vein thrombosis 
and pulmonary embolism.  They all were receiving a VKA and had a target INR of 2-
3, those requiring a higher target INR were excluded. The included patients’ time in 
therapeutic range (TTR) was 65% or lower. Indication for switching from VKA to 
rivaroxaban 20 mg od for secondary prevention of VTE were erratic INR control 
(median 13 [9-23] INR tests within the last 6 months) in 29 patients and INR 
constantly sub-therapeutic range in six patients.  
Patients were switched from VKA to rivaroxaban 20mgs daily and the patients were 
followed for a median of 10 months [6-24]. Women in the rivaroxaban arm were 
advised not to become pregnant.  
No further VTE, major bleeding events or serious side effects were seen except in two 
women there was a worsening of menorrhagia.  
 
Extreme caution should be applied in interpreting our preliminary observations. 
However, we consider that NOAs might represent a promising alternative in APS 
patients with previous venous thromboembolism. Results from the RAPS study will 
be available next year and will address this issue.  
Recently, Schaefer at al5. reported the failure of dabigatran and rivaroxaban for 
secondary thromboprophylaxis in three patients with APS. Our results disagree with 
their experience, probably due to the different subset of patients in the two studies. 
Two of three patients reported by Schaefer at al [5] had previous arterial thrombotic 
events (cerebral infarction and radial artery thrombosis). Previous arterial thrombosis 
was an exclusion criterion in our study, as we use an INR target of 3-4 in these 
patients when compared to patient with previous VTE. Therefore, until the equivalent 
dosing of NOAs to an INR of 3-4 is known, we will not be using NOAs for secondary 
thromboprophylaxis in patients with previous arterial event. Patient three was 
reported as having cirrhosis and oesophageal varices.  It is arguable to attribute the 
portal vein thrombosis to the failure of rivaroxaban only, as several additional factors 
might have contributed. Firstly, portal vein thrombosis is a common complication of 
liver cirrhosis [6]. Secondly, the sub-acute/chronic features shown at the venogram 
might call into questioning the timing of the event. Lastly, rivaroxaban was stopped 
for six days before admission.  
 
It is debatable if the detection of LA may be affected by rivaroxaban. We compared 
testing for LA in patients on rivaroxaban with their previous tests, when they were not 
receiving anticoagulation. Diagnostic accuracy for LA testing during rivaroxaban 
treatment is shown in Table 1. Taipan snake venom time (TSVT) had the best 
specificity and positive predictive value when compared to dilute activated partial 
thromboplastin time (dAPPT) and dilute Russell's viper venom time (dRVVT).  Our 
results support previous observations suggesting that Taipan/Ecarin time is poorly 
affected by the presence of rivaroxaban [7]. The observation that dRVVT is the test 
most affected by rivaroxaban [8] is not surprising, as Russell’s Viper Venom and 
rivaroxaban share the same target (factor Xa). However, in our study false positive 
results were seen with all types of LA testing, suggesting they cannot be used 
diagnostically while patients receive rivaroxaban; although this needs confirming in 
studies design specifically to address this question.  
 
In summary our study suggests the use of rivaroxaban therapy for secondary 
thromboprophylaxis for APS patients with previous VTE looks promising, but that 
LA testing in patients receiving rivaroxaban seems unreliable. In the interim, our 
observations suggest that rivaroxaban may be considered cautiously as an alternative 
anticoagulant in APS patients with previous VTE, who require a target INR of 2-3, 
but have poor anticoagulant control with VKA.  
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Table 1 
Diagnostic accuracy of lupus anticoagulant testing in patients with APS while on 
rivaroxaban comparing results with their previous tests, when they were not 
receiving anticoagulation. 
 Sensitivity (%) Specificity (%) NPP (%) PPV (%) 
dRVVT* 
 
94 50 88 69 
dAPPT* 
 
84 75 80 80 
TSVT 
 
58 93 65 91 
 
dAPPT, dilute activated partial thromboplastin time; dRVVT, Dilute Russell's 
viper venom time;  TSVT, Taipan snake venom time;  Negative predictive value, 
NPP, positive predictive value; PPV; results were not available in 3 patients. 
*includes screening, mixing and confirmation stages.  
 
 
